<DOC>
	<DOCNO>NCT00629226</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Radiation therapy use high energy x- ray kill tumor cell . Bortezomib cetuximab may make tumor cell sensitive radiation therapy . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together cetuximab , radiation therapy , cisplatin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together cetuximab radiation therapy without cisplatin treat patient stage IV head neck cancer .</brief_summary>
	<brief_title>Bortezomib , Cetuximab , Radiation Therapy With Without Cisplatin Treating Patients With Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate feasibility toxicity bortezomib , cetuximab , radiotherapy without cisplatin patient stage IV squamous cell carcinoma head neck . - To identify maximum tolerate dose bortezomib clinical phase II development . Secondary - To evaluate objective response rate , progression-free survival , overall survival patient treat regimen . - To determine effect bortezomib cetuximab without cisplatin inhibit activation NF-kB , EGFR , MAPK , STAT3 signal pathway , expression pro-survival pro-angiogenesis gene regulate pathway , proliferation , apoptosis , angiogenesis . OUTLINE : This multicenter , dose-escalation study bortezomib . Patients simultaneously accrue 1 2 treatment group . Patients initially accrue group I sufficient number patient establish maximum tolerate dose ( MTD ) bortezomib . Patients accrue group II . - Group I : Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 . Patients also receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 , 22 , 25 , 29 , 32 , 43 , 46 , 50 , 53 . Beginning day 8 9 , patient undergo standard intensity-modulated radiotherapy ( IMRT ) daily , 5 day week , 8 week . Once MTD bortezomib determine , least 6 10 additional patient accrue treated MTD . - Group II : Patients receive cetuximab , bortezomib ( begin one dose level MTD determine group I ) , IMRT group I . Patients also receive cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 . Once MTD bortezomib determine , 6 additional patient accrue treated MTD . Patients undergo blood sample collection periodically correlative laboratory study . Samples analyze biomarkers immunohistochemistry , quantitative reverse transcriptase-polymerase chain reaction , ELISA . After completion study therapy , patient follow periodically 2-5 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma head neck , include variant undifferentiated/poorly differentiate carcinoma Previously untreated stage IV disease OR residual disease regionally recurrent disease prior surgery and/or chemotherapy Must eligible receive fulldose radiotherapy evaluate accepted treatment Radiation Oncologist No clinically measurable distant disease OR asymptomatic small distant lesion outside radiation field ≤ 3 cm individual aggregate diameter palliation local regional disease clearly warrant No previously untreated nasopharyngeal cancer ( stage ) Recurrent nasopharyngeal carcinoma allow No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 70100 % ANC ≥ 1,500/mcL Platelet count ≥ 100,000/mcL Total bilirubin normal ( indirect bilirubin ≤ 3 mg/dL patient Gilbert 's syndrome ) AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Adequate cognitive neurologic function No history allergic reaction attribute compound similar chemical biologic composition bortezomib , cetuximab , cisplatin , agent use study No peripheral sensory neuropathy ≥ grade 2 No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would preclude study compliance HIVnegative PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) More 3 month since prior cisplatin No prior radiotherapy head neck No prior systemic EGFR inhibitor No prior bortezomib No concurrent investigational agent No concurrent anticancer therapy No concurrent antiretroviral therapy No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) No concurrent amifostine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>